Roche to Acquire GenMark Diagnostics LAST MONTH, Roche and GenMark Diagnostics announced a definitive merger agreement for Roche to acquire GenMark in a transaction valued at $1.8 billion. Roche called attention to GenMark’s syndromic panel testing portfolio and said this line of molecular tests would strengthen its products for infectious disease testing in hospitals, particularly …
Lab Briefs: Roche, GenMark Diagnostics, Thermo Fisher, Mesa Biotech, ProPath Read More »
To access this post, you must purchase The Dark Report.